PolyPeptide Group is a high-tech enterprise specializing in the development, manufacture and sale of therapeutically active peptides.

Pharmaceutical

PolyPeptide Group

Daniel Lasanow, Director Global Operations and Member of the Executive Committee of [PolyPeptide Group](/org/polypeptide-group) is a Belgian citizen born in 1962. Mr. Lasanow joined the company as Director Global Operations of Polypeptide Laboratories (Sweden) AB in 2016 from Siegfried Pharma, where he served as Senior Vice President, Multi-sites Managing Director. Prior to that, Mr. Lasanow served as Multi-sites Managing Director (2012 – 2015) and as Multi-sites Production & Technologies Director (2011 – 2012) at BASF Pharma, which later became part of Siegfried Pharma. Between 2009 and 2011, he served as Production Director, Belgium at NextPharma Technologies. Beginning in 2000, Mr. Lasanow was Production Director, Belgium at [Lonza](/org/lonza-group-ag) and UCB Bioproducts (which was later acquired by [Lonza](/org/lonza-group-ag)). He started his career in 1992 at GSK Pharmaceutical. Mr. Lasanow holds a Master of Sciences in Organic Chemistry from the University of Louvain, Belgium.

Daniel Lasanow

Christina Del Vecchio, General Counsel, Corporate Secretary, and member of the Executive Committee of PolyPeptide Group, is a Swiss and Swedish citizen born in 1978. She joined PolyPeptide Group on 1 September 2021 from Niederer Kraft Frey AG, a leading Swiss law firm based in Zurich, which she joined in 2013, becoming counsel in 2018. Prior to joining Niederer Kraft Frey AG, she was an associate at Latham & Watkins LLP in their London office. Over the course of her career, Christina has advised numerous Swiss and international companies on a wide range of commercial and financing transactions, securities laws, governance, compliance, and other legal matters. Christina Del Vecchio was born and raised in the US, she graduated from Columbia Law School in 2008, where she was recognized as a James Kent Scholar, and summa cum laude from the University of Florida in 2000 with a Bachelor of Arts.

Christina Del Vecchio

Neil Thompson, Director Global Sales, and Marketing and Member of the Executive Committee of PolyPeptide Group, is a British citizen born in 1972. Mr. Thompson joined PolyPeptide Group in 2004 and has held various sales and business development roles, most recently, since 2019, as Group Commercial Director. Before that, he served as Director Business Development Europe (2015 – 2019), Associate Director Business Development Europe (2010 – 2015), Business Manager Custom Development (2006 – 2010), and Regional Sales Manager (2004 – 2005). Before joining PolyPeptide, Mr. Thompson worked served as Assistant Production Manager / Peptide Product Manager at Bachem (1999 – 2003) and in various roles rising to Assistant Production Manager at Peninsula Laboratories Europe Ltd (1988 – 1999). Mr. Thompson holds a Bachelor of Science in Chemistry and Biochemistry from Liverpool John Moores University.

Neil Thompson

Peter Wilden, Chairman of the Board of Directors of PolyPeptide Group, is a German citizen born in 1957. Between 2000 and 2017, Mr. Wilden was Executive Vice President and CFO of Ferring Pharmaceuticals. Currently, Mr. Wilden is Executive Chairman of Ferring International Center SA, Saint-Prex (since 2002). He also serves as Vice Chairman of Schlumberger AG, Austria (since 2014), Vice Chairman of Project HOPE in the U.S. (since 2012), and Chairman of Project HOPE Suisse International Foundation (since 2015). Between 2004 and 2014, Mr. Wilden was a member of the Board of Directors and Chairman of the Audit Committee of Lonza Group AG, Basel. Mr. Wilden holds a Ph.D. in Economics and an MBA in Industrial Economics, both from the University of Kiel, Germany.

Peter Wilden

Jan Fuhr Miller, Chief Financial Officer and Member of the Executive Committee of [PolyPeptide Group](/org/polypeptide-group), is a Danish citizen born in 1970. Mr. Miller joined [PolyPeptide Group](/org/polypeptide-group) as CFO in 2015 from CMC Biologics A/S (Copenhagen), an independent biologics contract manufacturing organization, where he served as Vice President, Finance. Prior to that, Mr. Miller served as Nordic Financial Leader at Honeywell A/S from 2012 to 2013. Between 2000 and 2011 he served as Director, Finance & Logistics, Director, Finance & Business Administration, Senior Manager, Business Information & Technology, Manager, Marketing Research and Manager, Business Operations at H. Lundbeck A/S. He started his career in 1998 at Colgate-Palmolive. Mr. Miller holds a Master of Science from the University of Aarhus, School of Management, Denmark, and an MBA with a concentration in Finance from the Keller Graduate School of Management, Illinois.

Jan Fuhr Miller

Jane Salik transitioned from Chief Executive Officer to a Member of the Board in April of 2021. 

Jane Salik

Raymond De Vré, Chief Executive Officer of [PolyPeptide Group](/org/polypeptide-group), is a Belgian citizen born in 1968. Mr. De Vré joined [PolyPeptide Group](/org/polypeptide-group) on 1 April 2021 and became CEO on the day of its listing on 29 April 2021. He joined the company from Dr. Reddy’s Laboratories (DRL), a multinational pharmaceutical company, where he served as Senior Vice President, Head Biologics, and as a member of the Management Committee from 2018 to 2021. Prior to that, at DRL he was Senior Vice President Global Business Operations and Strategy, Biologics from 2017 to 2018 and Vice President Commercial, Biologics between 2012 and 2017. Before starting his tenure at DRL, Mr. De Vré was a Partner of [McKinsey & Company](/org/mckinsey-company) from 2004 until 2011 as well as a consultant from 1996 until 2003. In his roles at McKinsey, he advised companies in the areas of generics, pharmaceutical, biotech, and specialty chemicals across multiple geographies, especially Europe, the U.S., and India. Mr. De Vré holds a Ph.D. in Applied Physics from [Stanford University](/org/stanford), California, and a Master’s degree in Engineering from Université Libre de Bruxelles.

Raymond De Vré

Patrick Aebischer, Vice Chairman and Lead Independent Director of PolyPeptide Group, is a Swiss citizen born in 1954. Mr. Aebischer is a Professor of Neurosciences at École Polytechnique Fédérale de Lausanne (EFPL), Lausanne. He serves as a member of the Board of Directors of Nestlé AG, Cham (since 2015) and Logitech International SA, Apples (since 2016) and as Chairman of the Novartis Venture Fund (since 2014), Amazentis SA, Ecublens (since 2008), and Arctos Medical AG, Bern (since 2019). Mr. Aebischer further serves as senior partner of ND Capital, Fund-III (since 2017). Between 2008 and 2020, Mr. Aebischer served as a member of the Board of Directors of Lonza Group AG, Basel. Further, he was a founding scientist and member of the Board of Directors of CytoTherapeutics Inc. (between 1989 and 1999) and Modex Therapeutiques Inc. Between 2000 and 2016, he was president of EPFL and between 2004 and 2016, he served as a member of the Board of the Swiss Federal Institute of Technology (ETH). Mr. Aebischer holds a Doctorate degree in Medicine from the University of Geneva as well as four Honorary Doctorates from Universities worldwide.

Patrick Aebischer

Erik Schropp, a member of the Board of Directors of PolyPeptide Group, is a Dutch citizen born in 1964. Mr. Schropp has served as a member of the Board of Directors of PolyPeptide Laboratories Holding B.V. since 2017. Currently, he is CEO of C&P Investors Limited and a director of Draupnir Holding B.V., The Netherlands. Previously, Mr. Schropp held various finance functions in the pharmaceutical industry. Further, Mr. Schropp serves as a member of the Board of Directors of various privately held companies engaged in the fields of life sciences, gene therapy, and venture capital investment. Mr. Schropp holds a Master’s degree in Economics & Tax from the Erasmus University Rotterdam, The Netherlands.

Erik Schropp

Philippe A. Weber, Independent Member of the Board of Directors of PolyPeptide Group, is a Swiss citizen born in 1965. Mr. Weber is a member of the Board of Directors of Niederer Kraft Frey AG, Zurich (since 2008) and has been a Partner since 2002. He further serves as Company Secretary of CLS Group Holdings AG, Lucerne (since 2002), and as a Non-Executive Director of EDAG Engineering Group AG, Arbon (since 2015). Mr. Weber is the Vice Chairman of Leonteq AG, Zurich (since 2020). He is further a member of the Board of Directors of Medacta Group AG, Castel San Pietro (since 2019), Newron Suisse SA, Zurich (since 2007), NorthStar Holding AG, Roggwil (since 2018), and of Banca del Ceresio SA, Lugano (since 2017). Between 2004 and 2017, he served as a member of the Board of Directors of Robert Aebi AG, Regensdorf. Mr. Weber holds a Ph.D. in law from the University of Zurich and an LL.M. from the European University Institute in Fiesole, Italy.

Philippe Weber

The executive team at PolyPeptide Group has experience in finance and business administration from companies such as CMC Biologics and Honeywell. They have also completed degrees in areas such as finance and economics from institutions such as Keller Graduate School of Management and Aarhus University.

CEO and Executive Team

About

Team members

Other teams at PolyPeptide Group

Board of Directors

Leadership Team

Discover similar companies